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Abstract
MUC1 is associated with cellular transformation and tumorigenicity and is considered as an important tumor-associated
antigen (TAA) for cancer therapy. We previously reported that anti-MUC1 monoclonal antibody C595 (MAb C595) plus
docetaxel (DTX) increased efficacy of DTX alone and caused cultured human epithelial ovarian cancer (EOC) cells to undergo
apoptosis. To further study the mechanisms of this combination-mediated apoptosis, we investigated the effectiveness of
this combination therapy in vivo in an intraperitoneal (i.p.) EOC mouse model. OVCAR-3 cells were implanted
intraperitoneally in female athymic nude mice and allowed to grow tumor and ascites. Mice were then treated with
single MAb C595, DTX, combination test (MAb C595 and DTX), combination control (negative MAb IgG3 and DTX) or vehicle
control i.p for 3 weeks. Treated mice were killed 4 weeks post-treatment. Ascites volume, tumor weight, CA125 levels from
ascites and survival of animals were assessed. The expression of MUC1, CD31, Ki-67, TUNEL and apoptotic proteins in tumor
xenografts was evaluated by immunohistochemistry. MAb C595 alone inhibited i.p. tumor growth and ascites production in
a dose-dependent manner but did not obviously prevent tumor development. However, combination test significantly
reduced ascites volume, tumor growth and metastases, CA125 levels in ascites and improved survival of treated mice
compared with single agent-treated mice, combination control or vehicle control-treated mice (P,0.05). The data was in a
good agreement with that from cultured cells in vitro. The mechanisms behind the observed effects could be through
targeting MUC1 antigens, inhibition of tumor angiogenesis, and induction of apoptosis. Our results suggest that this
combination approach can effectively reduce tumor burden and ascites, prolong survival of animals through induction of
tumor apoptosis and necrosis, and may provide a potential therapy for advanced metastatic EOC.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological
malignancy and the fifth most common cause of cancer-related
deaths in women in the United States, resulting in an estimated
21,880 new cases and 13,850 deaths in 2009 [1]. Patients with
advanced disease have a response rate of more than 80% following
surgery and adjuvant chemotherapy with platinum-taxane, with a
median progression-free interval of 18 months [2]. Unfortunately,
the cancer will recur in the majority of these patients, and the
overall 5-year survival rate for patients with advanced stage disease
is only 23–30% [3]. Conventional cancer chemotherapy often
results in severe side effects related to non-specific modes of action.
Studies evaluating various cytotoxic agents in recurrent EOC have
found response rates of 10–28% with an accompanying progres-
sive increase in the number of drug-resistant tumors [4]. Thus,
novel therapeutic strategies are urgently needed to improve the
outcome for this deadly disease. A promising approach that may
improve patient outcome is the use of monoclonal antibodies
(MAbs) combined with traditional chemotherapy.
MUC1 is a large molecular weight transmembrane glycoprotein
that is overexpressed in many carcinomas [5,6] including EOC
[7–9], and mediates signal transduction events that stimulate the
motility, invasion, and metastasis of cancer cells [10]. MUC1 is
over-expressed on 90% of EOC cell surfaces [7,8]. The enhanced
levels of MUC1 expression by cancer cells may mask extra-cellular
domains from immune surveillance, conferring a survival
advantage on malignant cells and playing an important role in
the ability of tumors to invade and metastasize [11]. Thus, tumor-
associated MUC1 is a promising molecular target for a novel
therapy for EOC patients.
C595 is an IgG3, murine MAb raised against the protein core of
human MUC1 (urinary epithelial mucin1) [12]. Epitope mapping
has shown that C595 recognizes a tetrapeptide motif (RPAP)
within the protein core of MUC1 mucin that contains a large
domain of multiples of a highly conserved 20-amino-acid repeat
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has been labeled with c-emitting radioisotope (
111In) to test its
capacity for cancer localization and identification in 19 patients
with a clinical suspicion of ovarian malignancy, and achieved final
accuracies of 79% and 64% compared to magnetic resonance
imaging and ultrasound in relation to the final tumor histology
[14]. After labeling with a-emitter (
213Bi),
213Bi-C595 a-conjugate
(AC) has been used to target single prostate [15], pancreatic [16]
and ovarian cells [17] in vitro and regress pancreatic subcutaneous
xenografts in vivo [18]. These results support the hypothesis that
the MAb C595 is useful either alone or in combination with other
therapies to improve the treatment of the advanced EOC.
Although paclitaxel is used in first-line therapy, its analogue
docetaxel (DTX) has advantages, including slower cellular efflux
and higher solubility, allowing for higher intracellular concentra-
tions [19]. In clinical trials, DTX resulted in equivalent response
rates and has shown activity against paclitaxel-refractory carcino-
mas[20,21].DTXhasdemonstrated significantactivityinboth pre-
clinical and clinical studies for the treatment of numerous solid
malignancies including EOC [22–25]. It is plausible that DTX may
become part of the first-line therapy for EOC. DTX combined with
aplatinumcompound(suchascarboplatin)hasbecomethesystemic
chemotherapy of choice for primary EOC, with high efficacy.
However, dose-related toxicity and the eventual development of
resistance are major issues requiring attention in a gynecologic
oncology setting. Ultimately most of these patients will die of
metastatic disease. Maintaining low drug levels in the systemic
circulation through localized delivery can consequently decrease
toxic side effects, and increase local drug concentrations in the
peritoneum, where ovarian tumors and ascites reside. This can be
achievedthroughi.p.administration.TheNationalCancerInstitute
has recommended that i.p. chemotherapy be considered for the
treatment of advanced ovarian cancer [26]. Combination therapy
specifically employing strategies such as a chemotherapeutic agent
plus an antibody through i.p. administration may efficiently reduce
dose-limiting toxicity and improve treatment efficacy.
In a recent study, we demonstrated that MAb C595 alone could
kill EOC cells in a dose-dependent manner; this killing was also
dependent upon MUC1 expression levels. Low-dose MAb C595
combined with DTX increased EOC sensitivity to the chemo-
therapy drug and reduced the dose required [27]. In this study, we
hypothesized that this combination treatment can effectively work
in an in vivo EOC animal model. We found that MAb C595 could
inhibit i.p. tumor growth and ascites production in the OVCAR-3
mouse xenograft model and enhance the therapeutic efficacy of
DTX in a concentration-dependent manner, and that after i.p.
injection, this combination treatment (test) (MAb C595 and DTX)
could markedly reduce tumor burden and ascites and consequent-
ly prolong the survival of treated animals. Our results suggest that
this novel combination holds promise as a potential therapy for the
treatment of advanced metastatic EOC.
Materials and Methods
Drug
DTX was purchased from Sigma-Aldrich, Pty Ltd, Castle Hills,
NSW, Australia. The drug was first diluted in [hydroperoxymethyl
cellulose (HPMC) prepared as 0.5% in PBS] and stored at 4uC
for use.
Antibodies
MAb C595 was kindly provided by Nottingham University
(Nottingham, UK). Mouse anti-human IgG3 isotype control MAb
was purchased from Zymed Laboratories Inc (South San
Francisco, CA, USA). Rabbit anti-human Ki-67, caspase-3
(active), and PARP-1 (cleaved p85) MAbs were provided by
Epitomics (Burlingame, CA, USA). Rat anti-mouse CD31 MAb
was purchased from BD Pharmingen (Bedford, MA, USA). Swine
anti-goat, -mouse, -rabbit IgG/biotinylated, rabbit anti-rat IgG/
biotinylated, streptavidin/horseradish peroxidase (HRP) and
mouse IgG1 negative control MAb were purchased from
Dakopatts (Glostrup, Denmark).
Cell line and animal model
For all experiments, 6,8 weeks old female nude athymic
BALB/c nu/nu mice (Animal Resources Centre, Perth, Western
Australia) were used. The mice were housed and maintained in
laminar flow cabinets under specific pathogen-free conditions in
facilities approved by the University of New South Wales (UNSW)
Animal Care and Ethics Committee (ACEC). This study was
approved by ACEC, UNSW (ID: 08/110A). Animals were kept at
least 1 week before experimental procedure.
The primary OVCAR-3 EOC cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA), and the
sub-line of OVCAR-3 was selected and successfully established in
an i.p. xenograft model using nude mice in our laboratory [28].
This selection can increase the tumorigenicity of the OVCAR-3
cells in vivo. Briefly, viable OVCAR-3 cells (5610
6/500 mLi n
DPBS) were injected i.p. using a 1 mL syringe with a 26-gauge
needle and allowed to grow. Tumor progression was documented
once weekly for 10 weeks by measurements of abdominal
circumference for abdominal increase using a soft ruler. Upon
sacrifice, tumors were removed for weighting and proceeding for
histological testing.
Treatment protocols
Toxicity studies in nude mice without tumors: Toxicity studies
were performed to determine the maximum tolerance dose (MTD)
in mice for single MAb C595, mouse IgG3 negative control MAb,
DTX, combination test (MAb C595 and DTX) and combination
control (negative MAb IgG3 and DTX). The dose-tolerance
relationship was examined in nude mice (without tumors) for a
single i.p. administration of MAb C595, DTX and combination
treatment (test) compared with combination control treatment.
Groups of five mice received a total injected concentration of 1, 5,
10, 15, 20 mg/kg of MAb C595, or 3, 5, 7, 10, 15 mg/kg of DTX
as well as combined MAb C595 (1/3 of MTD i.e 5 mg/kg) or
5 mg/kg MAb IgG3 with 3, 5, 7, 10 mg/kg of DTX for 3 weeks.
The selected doses of MAbs were based on the MTD of single of
MAb C595 and DTX. Mouse weights were compared with those
at day 0 (first day of treatment administration) to determine
percentage weight change. The dose-limiting toxicity was defined
as end points: 15% loss of body weight or distressed behavior (i.e.,
loss of appetite and activity, hunched posture). The MTD was
defined as the highest dose at which one third of the cohort
reached dose-limiting toxicity end points [29]. After 10 weeks,
healthy mice were euthanized. The following experiments were
based on the MTD from the toxicity studies.
Efficacy studies in OVCAR-3 EOC animal model: After the
development of ascites, the peritoneal cavity was washed with
2 mL of sterile normal saline. The peritoneal contents were mixed
by managing gently and then completely aspirated [28]. Mice
were then randomly distributed into either the MAb C595 or
DTX alone single treatment group or the combination test (MAb
C595 and DTX) and combination control (MAb IgG3 and DTX)
group (n=10, per group). Different treatments were initiated
immediately after aspiration of the ascites fluid.
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high dose (HD) (15 mg/kg) MAb suspended in 1 mL of saline, and
the same volume of saline with 15 mg/kg of mouse MAb IgG3
(control) were administered once/week for 3 weeks.
b). For single DTX treatment, LD (5 mg/kg) or HD (10 mg/kg)
DTX suspended in 1 mL of HPMC (prepared as 0.5% in PBS) as
a vehicle and the same volume of HPMC as a control.
c). For the combination test (MAb C595 and DTX) and
combination control (MAb IgG3 and DTX) groups, the following
was used. Combination test included one single dose of MAb
C595 (1/3 dose of MTD, i.e. 5 mg/kg suspended in 0.5 mL of
saline) combined with one single dose of DTX (10 mg/kg DTX
suspended in 0.5 mL of HPMC). Combination control included
one single dose of MAb IgG3 (5 mg/kg suspended in 0.5 mL of
saline) combined with one single dose of DTX (10 mg/kg DTX
suspended in 0.5 mL of HPMC). The combination treatment (test
and control) was administrated sequentially from MAb C595 or
MAb IgG3 to DTX.
All treatments were performed i.p. and intended duration of
treatment was 4 weeks based on our previous studies. After
treatments, if an animal’s abdominal circumference reached
9.5 cm or if they were expected to become moribund within a
short time, animals were euthanized. Survival time of each animal
was calculated as the number of days elapsed between initiation of
treatment and euthanasia. At the end of the experiments, mice
were euthanized by cervical dislocation while under urethrane
anesthesia.
Sample collection
Before euthanasia, a blood sample was collected through
cardiac puncture under anesthesia. At the end of experiments,
2 mL of physiologic saline were injected i.p. and the peritoneal
cavity was completely washed and aspirated for CA125 detection.
Ascites volumes in the peritoneal cavity were recorded. The ascites
fluid wash, tumors dissected from the peritoneal cavity, and the
plasma, were all stored at 280uC for subsequent analysis.
Cumulative actual volume of ascites collected after each aspiration
was calculated by subtracting the 2 mL from the total volume
collected.
CA125 levels in ascites fluid
Tumor marker levels (CA125 Ku/L) in cell-free ascites fluid
from single MAb C595, DTX and combination treatments (test
and control) were determined by an ELISA assay following the
instructions at the St George Hospital Biochemistry Laboratories.
The concentration of CA125 in the ascites was normalized to the
actual volume of ascites collected.
Mouse tissues and histology
The tumor tissues from single MAb, DTX, combination or
vehicle control-treated animals were either immediately snap
frozen for frozen sections or fixed in 10% formalin for 24 hours,
embedded in paraffin block for H&E staining and immunohisto-
chemistry. Five-micrometer frozen sections of fresh tumor samples
were used for CD31 immunostaining. For toxicity studies, relevant
mouse organs such as kidney, liver, heart and bone marrow were
collected, formalin-fixed and sent for pathologic examination
(IDEXX Laboratories, Sydney, Australia).
Hematological toxicity and renal function examination
To determine hematological toxicity, 200 mL of blood in each
mouse was collected into K3 EDTA and Z serum gel minicollect
tubes (Greiner Bio-one, Germany) via the saphenous vein and
Microvette (SARSTEDT, Germany) before treatment and at 2
and 3 weeks post single or combination injection. Hematological
analyses of white blood cell (WBC), lymphocytes, red blood cell
(RBC), and platelet counts were performed. Blood was obtained at
the end of experiments for biochemical analysis of serum for renal
functions.
Immunohistochemistry
Standard immunoperoxidase procedures were used to visualize
MUC1, Ki-67, caspase-3 (active) and PARP-1 (cleaved p85).
Briefly, paraffin sections were deparaffinised in xylene, followed by
a graded series of alcohols (100%, 95%, and 75%) and re-hydrated
in water followed by Tris-buffered.
Saline (TBS) (pH 7.5). Slides were subsequently immersed in
boiling 0.01 M citrate buffer (pH 6.0) for 15 min to enhance
antigen retrieval, treated with 3% hydrogen peroxide and then
incubated with primary MAbs: MUC1 (1:500 dilution), Ki-67
(1:50 dilution), caspase-3 (active) (1:100 dilution) and PARP-1
(cleaved p85) (1:100 dilution), respectively overnight (o/n) at 4uC.
After washing with TBS, slides were incubated with swine anti-
goat, mouse, rabbit biotinylated IgG second antibody (1:150
dilution) for 45 min at room temperature (RT), and then with
avidin/ horseradish peroxidase (HRP) solution (1:300 dilution) for
30 min at RT. Sections were finally developed with 3,39
diaminobenzidine (DAB) substrate solution (Sigma-Aldrich, Pty
Ltd, Castle Hills, NSW, Australia), then counterstained with
hematoxylin; positive cells appeared brown. Control slides were
treated in an identical manner, and stained with the isotype MAb
or omission of the primary antibody as a negative control. Positive
controls were chosen depending on different MAbs, colon
carcinoma tissue for MUC1, tongue tissue for Ki-67 and DTX-
treated OVCAR-3 cell line for caspase-3 (active) and PARP-1
(cleaved p85).
For CD31 staining, the frozen sections were thawed, air-dried
and fixed in cold acetone for 10 min at RT. After a quick air dry
and washing with TBS, the sections were incubated with rat anti-
mouse CD31 MAb (1:100 dilution) o/n at 4uC. After rinsing with
TBS, sections were incubated with rabbit anti-rat biotinylated IgG
(1:200 dilution) for 45 min, and then with conjugated streptavi-
din/HRP (1:200 dilution) for another 30 min. Sections were
developed by using DAB solution (Sigma-Aldrich, Pty Ltd, Castle
Hills, NSW, Australia), and counterstained with hematoxylin.
Control slides were treated in an identical manner, and stained
with the isotype MAb or omission of the primary antibody as a
negative control.
TUNEL assay for apoptotic cells in vivo
Apoptosis was assessed on tumor xenograft tissues using the
TUNEL method with the TdT-fragEL in situ apoptotic detection
kit (Calbiochem, San Diego, CA, USA) according to the
manufacturer’s instructions. The specificity of TUNEL reactivity
was confirmed with appropriate negative (TdT omitted from the
labeling mix) and positive (treated HL-60 slides provided by the
company) controls. Slides were examined using a Leica light
microscope (Nussloch, Germany).
Assessment of immunostaining
Staining intensity (0–3) was assessed using light microscopy
(Leica microscope, Germany) at a640 objective as 2 (negative), +
(weak), ++ (moderate), and +++ (strong). Evaluation of tissue
staining was done, independently, by two experienced observers
(LW and HMC). All specimens were scored blind and an average
of grades was taken. If discordant results were obtained,
Combination Therapy for Human Ovarian Cancer
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third observer, experienced in immunohistochemical pathology.
Statistical analysis
All numerical data were expressed as the average of the values
obtained, and the standard deviation (SD) was calculated. The
data from treated and control groups were compared using the
two-tail student’s t test. All P values were 2-sided. One way
ANOVA, followed by the Dunnett’s post hoc test was performed
to determine significant differences in mean mice weight changes
in toxicological studies. Survival was calculated as the number of
days lapsed between initiation of treatment and euthanasia, and %
mice surviving was the number of animals remaining in each
group (610) at the end of each week following initiation of
treatment. P,0.05 was considered significant. All statistical
analyses were performed using the GraphPad Prism 4.00 package
(GraphPad, San Diego, CA, USA).
Results
Toxicological evaluation of single MAb C595, DTX and
combination treatments
Single-dose administration of MAb C595 at 1, 5, 10, 15 mg/kg
and DTX at 3, 5, 7, 10 mg/kg for the first 3 weeks did not reach
toxicity end points at 70 days post-treatment (Fig. 1A and B). A
single administration of control MAb IgG3 at 15 and 20 mg/kg for
the first 3 weeks did not reach toxicity end points at 70 days post-
treatment (data not shown). Mice treated with 20 mg/kg MAb
C595/week or 15 mg/kg DTX/week started to lose weight and
were euthanised 4 weeks post treatment because of signs of
distress; histopathological examination indicated mild nephropa-
thy in these groups. The results suggest that the MTD for single
dose MAb C595 lies between 15 and 20 mg/kg while the MTD
for a single administration of DTX lies between 10 and 15 mg/kg.
For the combination treatments, we used 1/3 MTD MAb C595
(i.e. 5 mg/kg) as a test and 5 mg/kg of negative MAb IgG3 as a
control combined with a range of DTX (1,10 mg/kg) to further
evaluate the toxicity of the combination treatments. No toxicity
was found in the combination treatments (Fig. 1C and D). There
were no macroscopic signs of chronic toxicity to major organs for
any mice. Leukocyte counts were depressed in peripheral blood in
treated mice at 2 weeks post injection, with recovery occurring by
4 weeks and normal hematology was seen at 70 days. These results
suggest that combination treatments with MAb C595 and DTX or
with control MAb IgG3 and DTX could be safely used in animal
models to study efficacy.
Effect of single MAb C595 and DTX on tumor growth
inhibition and ascites production
We firstly compared the antitumor activity of single MAb C595,
MAb IgG3 control, single DTX and vehicle control (HPMC)
following development of ascites and initial aspiration for 3 weeks.
Cumulative volume of ascites fluid produced per animal is
presented in Fig. 2A. Vehicle-treated mice continued to produce
ascites at a more frequent rate and had to be aspirated repeatedly
during the course of the treatment (28 days) while MAb C595-
Figure 1. Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks
in nude mice without tumors. Average percentage weight changes compared with day 0 (i.e., day of single or combination administration). A.
Dose-tolerance relationship in mice by single MAb C595. &: MAb C595 (1 mg/kg); m: MAb C595 (5 mg/kg); .: MAb C595 (10 mg/kg);¤: MAb C595
(15 mg/kg);N: MAb C595 (20 mg/kg). The significant difference was found between 20 mg/kg of MAb C595-treated group and other MAb C595-
treated groups (5–15 mg/kg) (P,0.05). B. Dose-tolerance relationship in mice by single DTX. &: DTX (3 mg/kg); m: DTX (5 mg/kg); .: DTX (7 mg/kg);
¤: DTX (10 mg/kg);N: DTX (15 mg/kg). The significant difference was found between 15 mg/kg of DTX-treated group and other DTX-treated groups
(5–15 mg/kg) (P,0.05). C. Dose-tolerance relationship in mice by combination test [MAb C595 (5 mg/kg)+DTX (3–10 mg/kg)]. &: MAb C595+DTX
(3 mg/kg); m: MAb C595+DTX (5 mg/kg); .: MAb C595+DTX (7 mg/kg); ¤: MAb C595+DTX (10 mg/kg). D. Dose-tolerance relationship in mice by
combination control [MAb IgG3 control (5 mg/kg)+DTX (3–10 mg/kg)]. &: MAb IgG3+DTX (3 mg/kg); m: MAb IgG3+DTX (5 mg/kg); .: MAb
IgG3+DTX (7 mg/kg); ¤: MAb IgG3+DTX (10 mg/kg). Points, mean (n=5 in each group); bar, SD.
doi:10.1371/journal.pone.0024405.g001
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C595 (461 mL for HD and 561 mL for LD, respectively)
compared with MAb IgG3 control mice (762 mL) (Fig. 2A).
DTX-treated mice developed ascites slowly compared with
HPMC control (661 mL) and the production of ascites was
related with the dose of DTX (261 mL for HD and 461 mL for
LD, respectively) (Fig. 2A). The HD of DTX (10 mg/kg)
significantly reduced the development of ascites (P,0.05,
Fig. 2A). In addition to ascites production, we also evaluated the
total tumor weight change in each group at the end of the
experiments (4 weeks after treatment). The tumor weight change is
consistent with the change of ascites production (Fig. 2B). Single
MAb C595 only partially inhibited the growth of OVCAR-3
tumors, as evidenced by tumor weight of 380680 mg in LD
(5 mg/kg) and 260676 mg in HD (150 mg/kg) versus 5606
77 mg in mice receiving negative MAb IgG3 control (15 mg/kg)
(P,0.05), respectively while single DTX obviously inhibited the
growth of OVCAR-3 tumors, as evidenced by tumor weight of
230666 mg in LD (5 mg/kg) and 75614 mg in HD (10 mg/kg)
versus 540696 mg in mice receiving the same volume of HPMC
(P,0.05), respectively (Fig. 2B). These results suggest that both
MAb C595 and DTX can induce regression of OVCAR-3 tumor
growth in a dose-dependent manner and that anti-tumor activity
of DTX is more effective than that of MAb C595.
Effect of combination of MAb C595 and DTX on tumor
growth, ascites production and survival
We then compared the antitumor activity of the combination of
1/3 MTD MAb C595 (5 mg/kg) or control MAb IgG3 (5 mg/kg)
with one dose DTX (10 mg/kg) following development of ascites
and initial aspiration for 3 weeks. The combination test (5 mg/kg
MAb C595 and 10 mg/kg DTX) could significantly inhibit the
development of ascites compared with combination control
(5 mg/kg MAb IgG3 and 10 mg/kg DTX) and vehicle control
(Fig. 3A). The pattern of ascites production in the combination
control group is similar to that seen for a single 10 mg/kg DTX
treatment as described above. Cumulative volume of ascites fluid
produced per animal are presented for combination test
(0.460.2 mL), combination control (261 mL) and vehicle control
(762 mL) in Fig. 3B (P,0.05). Four weeks after treatment,
combination test treatment significantly inhibited the growth of
OVCAR-3 tumors, as evidenced by tumor weight of 15611 mg
versus 65616 mg in the combination control group and
5606100 mg in the vehicle control group (P,0.05), respectively
(Fig. 4A and B). The survival of animals was much better in the
combination test group than the combination control and vehicle
control groups (P,0.05) (Fig. 4C).
Single or combination treatment affects tumor marker
CA125 levels
At the end of experiments, change in mean CA125 levels for
single MAb C595 in LD was not significantly different compared
to MAb IgG3 control, whereas the change in mean CA125 levels
for single CA125 in HD or single DTX was obviously different
compared to MAb IgG3 or HPMC control, respectively (P,0.05)
(Fig. 2C). It is evident that the combination test group had
significantly inhibited CA125 levels compared with the combina-
tion control group (P,0.05) or vehicle control group (P,0.01)
(Fig. 3C). At euthanasia, the CA125 vehicle values were 68,0006
12,000 Ku/L, compared to the combination test and combination
control of 14,03065,022 Ku/L and 28,306611,403 Ku/L, res-
pectively. The reduction in cell-free ascites fluid CA125 levels is
consistent with the reduction in ascites volume and tumor weight.
Histological alterations in tumor xenografts after
combination treatment
To compare the histology of each group, we harvested tumors
from combination-treated, MAb C595 control-treated and vehicle
control-treated mice at the end of the experiments and stained
paraffin sections with H&E. As assessed by light microscopy
(Fig. 5), many targeted lesions were found to be considerably less
cellular and composed primarily of acellular material in combi-
nation test-treated xenografts and cells were most commonly
found in small islands whereas less targeted lesions were found in
combination control-treated xenografts (Fig. 5A). In contrast,
tumors from mice given vehicle control consisted of tightly packed
cells, with many blood vessels apparent within the tumors (Fig. 5A).
Low number of targeted lesions was found in single MAb C595-
treated mice (Fig. 5A). These results indicated a very large
difference in tumor cell burden among different treatments and
showed that combination test treatment obviously affected tumor
growth.
MUC1 changes after combination treatment
At the end of experiments, the percentage of MUC1 positive
staining cells visualized using MAb C595, in tumor xenografts
from combination test, combination control, MAb C595 control
and vehicle control groups was ,5%, 10,16%, 30–40% and
70,80%, respectively (Table 1). The expression of MUC1 in
combination test was remarkably reduced compared with that in
combination control, MAb C595 control and vehicle control
(P,0.05) (Fig. 5B). These results indicate that combination test
including MAb C595 can specific target cancer surface MUC1
and reduce MUC1 expression.
Assessment of tumor vascular density after combination
treatment
Representative micrographs from sections of excised tumor
xenografts of combination test, combination control and vehicle
control-treated mice immunostained with MAb CD31 are shown
in Fig. 5C. The numbers of positive staining cells/area in
combination test, combination control, MAb C595 control and
vehicle control groups were 3,5, 8,12, 15,20 and 30,40%,
respectively. The staining results are summarized in Table 1. A
marked reduction in the number of CD31
+ blood vessels was seen
in tumors from combination test group compared to combination
Figure 2. Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX
treatment in OVCAR-3 animal model. Following euthanasia, the peritoneal cavity of each mouse was washed with 2 mL of normal saline, and
after aspiration, the volume of ascites present was recorded. A. Cumulative volumes of ascites collected from each animal from initiation of therapy
[MAb C595 (H and L), MAb IgG3, DTX (H and L) are shown. The obvious difference was seen between DTX(H)-treated group and others-treated group
(P,0.05). B. Tumor weights (mg) at the end of experiments after single MAb C595, MAb IgG3, DTX or vehicle treatments with different doses. The
tumor weigh was obviously lower in MAb-treated and DTX-treated groups compared to MAbIgG3-treated and HPMC-treated control groups
(P,0.05). C. Effect of single MAb C595, MAb IgG3, DTX or vehicle on suppressing the increase in the tumor marker CA125 (CA125 Ku/L) in the ascites
fluid (peritoneal wash) at the end of experiments. The level of CA125 was obviously lower in MAb C595 (H)-treated and DTX-treated groups
compared to MAbIgG3-treated and HPMC-treated control groups (P,0.05). H: high dose; L: low dose. Representative graphs are shown.
doi:10.1371/journal.pone.0024405.g002
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(Fig. 5C). These results suggest that combination test targets
angiogenesis in OVCAR-3 model.
Assessment of cell death, proliferation and apoptotic
proteins after combination treatment
To investigate the effect of combination treatment on tumor cell
proliferation, tumor sections from nude mice were assessed for Ki-
67 expression, which is an indicator of underlying cell DNA
synthesis. Antibody against Ki-67 recognizes G1, S, G2 and M
phases, but not the G0 cells out of the cell cycle [30]. After 4 weeks
of treatment, very low numbers of Ki-67+ tumor cells were seen in
combination test (5,10%) mice, modest Ki-67+ tumor cells in
combination control (15,20%) and MAb C595 treated (25,36%)
mice, and many Ki-67+ tumor cells were seen in vehicle control-
treated (72,85%) mice (P,0.05), respectively (Table 1). Repre-
sentative images are shown in Fig. 6A.
To investigate if the mechanisms involved in the induction of
apoptosis in targeted lesions of tumor xenografts represented a
phenotypic response of OVCAR-3 tumors, the TUNEL assay was
performed. Representative results are shown in Fig. 6B. After
treatment, the tumor cells in combination test-treated (7,10/area)
mice showed typical apoptotic cell morphology with nuclear
chromatin condensation and fragmentation, and tumor cells in
combination control-treated (4,6/area) and MAb C595 control-
treated (3,5/area) mice showed fewer apoptotic cells whilst
tumors treated with vehicle control-treated did not (P,0.05)
(Fig. 6B, Table 1). To further confirm apoptosis as a main mode of
cell death following treatment, we observed high levels of caspase-
3 (active) and PARP-1 (cleaved p85) positive cells in combination
test-treated (74,90%) xenografts, low levels of caspase-3 (active)
and PARP-1 (cleaved p85) positive cells in combination control
and MAb C595-treated (30,48%) xenografts and caspase-3
(active) and PARP-1 (cleaved p85) negative cells in vehicle
control-treated xenografts (P,0.05) (Fig. 6C and D). The decline
in ascites production, tumor weight and vascular density was
associated with a rapid decrease in Ki-67 expression (cell
proliferation) and increases in TUNEL-positive lesions and
expression of apoptotic proteins: caspase-3 (active) and PARP-1
(cleaved p85). The staining results for Ki-67, TUNEL, caspase-3
(active) and PARP-1 (cleaved p85) are summarized in Table 1.
Discussion
Our recent results demonstrated that MAb C595 alone could
kill EOC cells in a dose-dependent manner and that low-dose
MAb C595 combined with DTX increased the sensitivity of
several EOC cell lines and induced apoptosis in vitro [27]. In the
present study, we further investigated whether MAb C595,
combined with DTX, would be more efficient than DTX alone
in killing EOC tumors in a xenograft animal mode previously
developed by our laboratory [28]. EOCs account for 90% of all
ovarian cancers, and can spread directly to adjacent organs;
‘seeding’ of the peritoneal cavity is frequently associated with
ascites formation, the most common feature of ovarian carcinoma,
particularly serous carcinoma [31]. Intra-abdominal dissemination
is the primary cause of death for patients with EOC, although the
exact mechanisms involved in EOC progression remain unclear.
The OVCAR-3 i.p. xenograft model we developed has 100%
tumor take, and can produce ascites and mimic the EOC spread in
the peritoneal cavity, and thus is an appropriate model to
investigate novel anti-ovarian cancer therapies.
Budiu et al (2011) found that increased serum MUC1 and high
anti-MUC1 antibody levels are potential prognostic biomarkers
for poor clinical response and reduced overall survival in
platinum-resistant or platinum-refractory ovarian cancer [32].
We recently demonstrated that MAb C595 is strongly positive in
over 90% of late stage of EOC sections as well as human EOC cell
lines from primary tumors and metastatic lesions, while no staining
was found in normal ovaries [8,27]. In the present study, we also
demonstrated MUC1 expression on OVCAR-3 tumor xenografts
using MAb C595 and confirmed the target antigens (MUC1) exist
after OVCAR-3 cells seed in peritoneal cavity (see Fig. 5B).
MUC1 is an important marker of malignancy and is a target for
several immunotherapies currently under investigation [33].
Gulley et al (2008) reported that in a pilot clinical study vaccination
with recombinant CEA-MUC-1-TRICOM poxviral-based vac-
cines were effective in the treatment of EOC [34]. These data
suggest that MUC1 is an interesting therapeutic target for EOC
therapy and that MAb C595 has the potential to target MUC1-
positive cancer cells in an animal model and can increase
sensitivity to current chemotherapeutic agents.
Based on our cytotoxicity study, we evaluated the anti-tumor
effects of single MAb C595 in LD (5 mg/kg) and HD (10 mg/kg)
after 3 weeks cell inoculation in OVCAR-3 model and found that
both LD and HD only partially prevented the production of ascites
and reduced tumor weight at the end of experiments compared
with the same amounts of MAb IgG3 control. These results
indicate that MAb C595 alone cannot effectively target OVCAR-
3 tumors in vivo (see Fig. 2). From previous observations, we know
that OVCAR-3 cells in an animal model can form solid tumors
after 1 week inoculation and that the solid tumors attain large
volumes after 3 weeks inoculation. Due to penetration problems,
MAb C595 cannot effectively target solid tumors, although MAb
C595 can effectively kill monolayer EOC cells in vitro [27].
The mechanisms of action of MAb C595 on MUC1-positive
EOC cells in the current study are unclear. We do not know
whether MAb C595 can be internalized in cancer cells and
trafficked after binding the cell surface MUC1, similar to MAb
J591 [35] or how it can inhibit MUC1 signalling via different
signalling pathways. However, many factors, including antigen
affinity and antigen density play important roles in the killing of
targeted antigen-positive cells. One possible explanation may be
that MAb C595 binding MUC1 either blocks or stimulates a
particular cell membrane molecule (e.g. growth factor receptor)
through its cytoplasmic tail, inhibiting tumor growth. Another
possibility is that in the presence of MAb C595, MUC1 and
EGFR can be alternatively trafficked, and enter the lysosomal
degradation pathway, with subsequent enhanced degradation.
This would imply that targeting MUC1 signalling pathways by
MAb C595 may reduce cancer proliferation, migration and
invasion of metastatic EOC cells. MAb C595 may also have a
Figure 3. Cumulative ascites volume and CA125 levels at the end of experiments after combination test and combination control
treatments. A. At the end of experiments, no obvious signs of ascites formation are seen in combination test (5 mg/kg MAb C595+10 mg/kg DTX)-
treated mice (a); signs of ascites formation was found in combination control (5 mg/kg MAb C595+10 mg/kg DTX)-treated mice (b); obvious signs of
ascites formation was found in vehicle (1/2 saline+1/2 HPMC)-treated mice (c). B. The cumulative ascites volumes from combination test, combination
control or vehicle-treated mice are shown (P,0.05). C. Effect of combination test, combination control or vehicle on suppressing the increase in
tumor marker level (CA 125 Ku/L) in the ascites fluid (peritoneal wash) at the end of experiments (P,0.05). Representative image and graphs are
shown.
doi:10.1371/journal.pone.0024405.g003
Combination Therapy for Human Ovarian Cancer
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24405Figure 4. Tumor weight and survival curve in combination test (control). A. Tumor weight changes at the end of experiments after
combination test, combination control or vehicle treatments with different doses (P,0.05). B. The tumor volume in combination test-treated mice
was significantly lower than in vehicle control-treated mice (P,0.01). C. For all animals, the intended duration of treatment was 4 weeks. Mice (10 per
group) were euthanized if due to ill health, they were expected to become moribund within a short time. Survival was calculated as the number of
days lapsed between initiation of treatment and euthanasia, and % mice surviving was the number of animals remaining in each group (610) at the
end of each week following initiation of treatment. The survival rate of animals in the combination test group was much better than that in the
combination control group or vehicle group (P,0.05). Representative images and graph are shown.
doi:10.1371/journal.pone.0024405.g004
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MUC1 MAb C595 has been reported in oral squamous cell
carcinomas (OSCCs), where MAb C595 induced complement-
dependent cytotoxicity (CDC) and antibody-dependent cellular
cytotoxicity (ADCC) to OSCC cells; this effect was strongly
correlated with MUC1 expression [36]. Furthermore, a human-
ized anti-MUC1 MAb (huHMFG-1) induced strong ADCC to
breast cancer cells and is currently being used in a clinical trial for
breast cancer [37]. These results suggest that in the clinical context
MAb C595 may also induce specific immune response to attach
MUC1-positive EOC cells. In contrast, Thie et al (2011) recently
demonstrated that a human anti-MUC1 scFv antibody reacted
with tumor cells in more than 80% of 228 tissue sections of
mamma carcinoma samples but showed no significant decrease in
tumor growth or increase in the survival rates in mouse xenograft
models using MCF-7 and OVCAR-3 tumor cells [38]. One of the
Figure 5. Representative images of histological changes, MUC1 and CD31 expression at the end of experiments after combination
and control treatments. A. Obvious targeted lesions are shown in combination test; medium targeted are shown in combination control and MAb
C595 control while non targeted lesions are shown in vehicle control. B. Very low MUC1 expression is shown in combination test; low MUC1
expression is shown in combination control and MAb C595 control while high MUC1 expression is shown in vehicle control (P,0.05). C. Markedly
reduced CD31 expression is shown in combination test; very low CD31 expression is shown in combination control; very low to medium CD31
expression is shown in MAb C595 control while high CD31 expression is shown in vehicle control (P,0.05). Brown color staining indicates positive
while blue hematoxylin stains nuclei. Magnification 620 in A; Magnification 640 in B, C. Representative images are shown.
doi:10.1371/journal.pone.0024405.g005
Table 1. The intensity of immunohistochemical staining of MUC1, CD31, Ki-67, TUNEL, Caspase-3 (Active) and PARP-1 (Cleaved
p85) in tumor xenografts from combination test, combination control, MAb C595 control and vehicle control.
Tumor (n=5) MUC1 CD31 Ki-67 TUNEL Caspase-3 (A) PARP-1 (C)
Combination test* + + + +++ ++,+++ ++,+++
,%5 3–5/area 5–10% 7–10/area 74–88% 80–90%
Combination control + + + ++ +,++ +
10–16% 8–12/area 15–20% 4–6/area 35–48% 30–45%
MAb C595 control +,++ ++,+++ +,++ ++,+++ + +
30–40% 15–20/area 25–36% 3–5/area 15–23% 10–16%
Vehicle control ++,+++ ++,+++ ++,+++ + 22
70–80% 30–40/area 72–85% 0/area 0 0
All sections were prepared at the end of experiments.
Abbreviations: 2, negative; +, weak; ++, moderate; +++, strong.
*indicates that obvious difference was found between combination test and controls.
A: active; C: Cleaved p85.
doi:10.1371/journal.pone.0024405.t001
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ADCC, as detected in vitro for MCF-7 cells [38]. Another possible
reason may be that MAb C595 has a different epitope for binding
to stimulate immune response compared to this human anti-
MUC1 scFv antibody.
DTX is now considered the preferred chemotherapeutic agent
for EOC [23,39]. The most widely described mechanism by which
DTX achieves this effect is through its activity as a mitotic spindle
poison, disrupting microtubule dynamics and inducing G2/M cell
cycle arrest, a downstream effect thought to be related to the
phosphorylation of Bcl-2 [40]. As we expected, DTX could
prevent the production of ascites and inhibit tumor growth in a
dose dependent manner compared with vehicle control and single
MAb C595 treatment (P,0.05, see Fig. 2). Because of MTD
limitation and side-effects of DTX in clinical condition, we further
investigated the effect of combination test with low dose (1/3
MTD, 5 mg/kg) MAb C595 and high dose DTX (MTD, 10 mg/
kg) on OVCAR-3 tumor development and survival of animals.
Our results indicate that this combination test can significantly
prevent production of ascites, regress tumor growth and improve
the survival of animals compared with the combination control
(5 mg/ kg IgG3 and 10 mg/kg DTX) and vehicle control (P,
0.05, see Fig. 3). This finding suggests that the combination of
MAb C595 and DTX is a promising therapy for the late stage,
drug resistant and recurrent EOC disease.
CA125 is a biomarker which can be used to monitor EOC
progression. It is a surface mucin-like glycoprotein antigen that is
expressed in more than 95% of all nonmucinous stage III/IV
EOCs [41]. The serum level of CA125 is well established as a
highly useful surrogate for monitoring the response to treatment
and confirming relapse in EOC [42,43]. The CA125 from ascites
in our study was produced from the secretion of OVCAR-3
xenograft tumors and can be used as a surrogate for monitoring
EOC progression after single or combination treatment. This
biomarker was used in the same model in our previous study,
where its efficiency for monitoring EOC progression was
demonstrated [28]. In the present study, the CA125 levels were
consistent with the production of ascites, tumor growth and
survival of animals with single and combination treatments,
suggesting that the CA125 is a useful marker to monitor the
response to the treatment or relapse in the OVCAR-3 animal
model.
The response of tumor growth to the combination test
treatment in this study was specific, and highly dependent on
antigenic expression. At the end of the experiments, most of the
tumor antigen expression (MUC1) in the lesions had disappeared
Figure 6. Representative images of Ki-67, TUNEL, Caspase-3 (Active) and PARP-1 (Cleaved 85) at the end of experiments after
combination and control treatments. A. Very low Ki-67 expression is seen in the combination test; reduced Ki-67 expression in the combination
control and MAb C595 control while high Ki-67 expression is seen in the vehicle control (P,0.05). B. Obvious TUNEL-positive cells are shown in
combination test; some TUNEL-positive cells are shown in the combination control and MAb C595 control while no TUNEL-positive cells are seen in
the vehicle control (P,0.05). C. High caspase-3 (active) expression is shown in combination test; low caspase-3 (active) expression is shown in
combination control and MAb C595 control while negative caspase-3 (active) expression is shown in vehicle control (P,0.05). D. High PARP-1
(cleaved p85) expression is shown in combination test; low PARP-1 (cleaved p85) expression is shown in combination control and MAb C595 control
while negative PARP-1 (cleaved p85) expression is shown in vehicle control (P,0.05). The brown color indicates nuclear staining in Ki-67, caspase-3
(active) and PARP-1 (cleaved p85), while blue indicates nuclear staining with hematoxylin. In the TUNEL assay, the brown color indicates nuclear
chromatin condensation and fragmentation with methylgreen nuclear staining. Magnification620 in B; Magnification640 in A, C, D. Representative
images are shown.
doi:10.1371/journal.pone.0024405.g006
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debris were found positive in these areas. These results suggest that
combination treatment can specifically target tumor-associated
antigen (MUC1) positive cancer cells.
Angiogenesis promotes the recovery of tumors following cytotoxic
attacks, and it provides adequate nutritional and oxygen supply
essential for tumor proliferation and metastasis [44]. In fact, the
angiogenic potential of a tumor is directly correlated with poor
prognosis[45].DeSouzaetal(2010)haverecentlydemonstratedthat
continuous DTX abrogates EOC tumor cell proliferation and
angiogenesis to the tumor microenvironment in a SKOV-3
xenograft model, leading to greater tumor cell death than
intermittent DTX therapy [25]. The effect of MAb C595 on tumor
angiogenesis is still unclear. In the present study, we found that
microvessel density (MVD) (CD31 expression) in combination test-
targeted lesions was much less than with control treatments. These
results suggest that MAb C595 may have a similar anti-angiogenesis
function asseen for DTX,and both MAb C595 andDTX may have
a concordant effecton tumorangiogenesis. MAb C595 may increase
the efficacy of DTX in anti-angiogenesis in this animal model. The
exactmechanismsofthecombinationtreatmentonangiogenesisand
vascular regression will be investigated in a future study.
In this study, we found scattered targeted lesions with
destruction of tissue structure and cell debris (necrosis) after 4
weeks treatment with combination therapy; fewer lesions were
seen in combination control and MAb C595 control groups at the
same time point. Other non-targeted areas showed ‘‘normal’’
tumor structure. The tumors treated with vehicle control also
showed features of untargeted tissue structure. These results
suggest that combination test can specifically and effectively kill
EOC cells in xenografts.
As described above, treatment with combination test could
effectively prevent production of ascites, delay tumor growth,
reduce the volume of tumor xenografts and CA125 levels in ascite
fluids and reduce vascularity of the tumor tissues. While the
potential mechanisms for this remain unclear, we conducted
preliminary studies to determine whether apoptosis was involved.
We recently demonstrated that the combined MAb C595 and
DTX could induce high levels of TUNEL-positive cells in single
monolayer cultured EOC cells [27], suggesting apoptosis as a
possible mode of cell death. In the present study, the therapeutic
efficacy of the combination therapy included apoptosis and
necrosis, and the number of apoptotic cells (TUNEL-positive)
and the caspase-3 (active) and PARP-1 (cleaved p85) positive cells
in OVCAR-3 tumors increased while the number of proliferating
cells (using the Ki-67 marker) decreased. Caspase-3 is a member of
the apoptosis execution functional group of caspases, and is either
partially or totally responsible for the proteolytic cleavage of many
key proteins during apoptosis [46]. It is activated by proteolytic
cleavage into two active subunits only when cells undergo
apoptosis [47]. PARP-1 is a marker for apoptosis that can be
immediately activated by DNA strand breaks; the degree of
PARP-1 activation could be an important factor in the cell’s ability
to repair the damage and survive or to die [48]. PARP-1 activation
following limited DNA injury could constitute a signal to activate
the repair and cell cycle control machineries. Apoptosis contrib-
utes to tumor volume reduction and can aid drug penetration into
tumors by decreasing tumor cell density and expanding the tumor
interstitium [49]. These results suggest that the mechanisms of
action of the combination test in OVCAR-3 animal model involve
in apoptosis and related with caspase-3 and PARP-1apoptotic
proteins.
In summary, we have demonstrated for the first time that
combining MAb C595 and DTX can effectively inhibit intraper-
itoneal tumor growth and ascites production, and prolong survival
of animals in a mouse xenograft EOC model. Furthermore, this
combination treatment can target tumor-associated antigens
(MUC1), reduce angiogenesis and induce apoptosis. This
combination treatment may provide a basis for reducing the dose
of DTX required, without adversely impacting on treatment
efficacy. Consequently, this combination treatment may be a
potent therapeutic agent against advanced, recurrent, metastatic
EOC disease.
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